Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,310 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Disorders Clear all
Completed Not applicable Interventional Results available

Resident Surveillance of Pediatric Patient Developmental Status at the Two Month Preventive Care Visit

NCT00465361
View directory record Official record
Conditions
Growth & Development, Child Development, Internship and Residency, Education, Medical, Developmental Disabilities
Interventions
performance feedback with an educational module
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 22, 2026, 1:22 AM EDT
Completed Phase 4 Interventional Results available

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 22, 2026, 1:22 AM EDT
Terminated Not applicable Interventional Results available

CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory Myelopathies

NCT01440452
View directory record Official record
Conditions
Inflammatory Myelopathies
Interventions
FES Cycling, Cycling without FES, Lumbar puncture, Mood assessment
Device · Procedure · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 22, 2026, 1:22 AM EDT
Terminated Phase 2 Interventional Results available

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

NCT00398047
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
Azacitadine and Hematopoietic Growth Factors
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 22, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

NCT00496587
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Capecitabine, Gemcitabine, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 22, 2026, 1:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation

NCT01850706
View directory record Official record
Conditions
Detrusor Overactivity
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 22, 2026, 1:22 AM EDT
Active, not recruiting Phase 2 Interventional

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

NCT05607004
View directory record Official record
Conditions
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
(Z)-endoxifen, goserelin
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 1:22 AM EDT
Terminated No phase listed Observational

Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas

NCT00646308
View directory record Official record
Conditions
Growth Hormone Deficiency, Pituitary Tumor
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 22, 2026, 1:22 AM EDT
Completed Early Phase 1 Interventional

Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal

NCT02534376
View directory record Official record
Conditions
Prostate Cancer
Interventions
ezetimibe 10mg-simvastatin 40mg
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 22, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy

NCT00486304
View directory record Official record
Conditions
Cachexia, Head and Neck Cancer, Weight Changes
Interventions
ADD, Placebo
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 22, 2026, 1:22 AM EDT
Completed Phase 2 Interventional

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

NCT05963984
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions
Samuraciclib, Fulvestrant
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 22, 2026, 1:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01946152
View directory record Official record
Conditions
Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Dexamethasone, Filgrastim-sndz, Laboratory Biomarker Analysis, Pomalidomide
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 22, 2026, 1:22 AM EDT
Terminated Not applicable Interventional

Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia

NCT03532555
View directory record Official record
Conditions
Infant,Premature, Bronchopulmonary Dysplasia, Growth Failure
Interventions
Zinc Acetate, No supplemental zinc
Dietary Supplement · Other
Lead sponsor
University of Utah
Other
Eligibility
14 Days to 28 Days
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 22, 2026, 1:22 AM EDT
Completed No phase listed Observational Results available

Acromegaly Treatment Quality of Life Study

NCT01732406
View directory record Official record
Conditions
Acromegaly
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 22, 2026, 1:22 AM EDT
Recruiting Phase 1 Interventional

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

NCT07224776
View directory record Official record
Conditions
Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
Interventions
sparsentan, No sparsentan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 1:22 AM EDT
Completed Phase 1 Interventional Results available

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

NCT01730118
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu Expression
Interventions
Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 22, 2026, 1:22 AM EDT
Withdrawn Not applicable Interventional

Assisted Exercise in Prematurity; Effects and Mechanisms

NCT00580099
View directory record Official record
Conditions
Growth, Development
Interventions
assisted exercise, cuddle
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
30 Weeks to 35 Weeks
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 22, 2026, 1:22 AM EDT
Completed No phase listed Observational

National Cooperative Growth Study in CKD

NCT00616278
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
1 Day to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 22, 2026, 1:22 AM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 22, 2026, 1:22 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

NCT04704921
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
ABBV-RGX-314, Ranibizumab (LUCENTIS®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
89
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 22, 2026, 1:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

NCT01865747
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Cabozantinib tablets, Everolimus (Afinitor) tablets
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
59
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 22, 2026, 1:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

NCT00659555
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, Ketoconozole tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 22, 2026, 1:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alkaline Phosphatase Level in Pregnancy and Its Association With Birth Weight

NCT03187938
View directory record Official record
Conditions
Low Birth Weight Infants
Interventions
Testing of Alkaline Phosphatase Levels
Diagnostic Test
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 22, 2026, 1:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Targeted Nutrition for Moderate to Late Preterm Infants

NCT05515614
View directory record Official record
Conditions
Premature Birth, Breastmilk Collection, Postnatal Growth Restriction
Interventions
Targeted Fortification, Enfamil Liquid Human Milk Fortifier
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 22, 2026, 1:22 AM EDT